IRIS
GOBBI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 22.712
Totale 22.712
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 22.712
Totale 22.712
Salva come PNG Salva come JPEG
Città #
Genova 18.716
Rapallo 2.358
Genoa 1.582
Bordighera 56
Totale 22.712
Salva come PNG Salva come JPEG
Nome #
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. 164
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 164
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 162
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts 151
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 150
M-2 protocol for melphalan-resistant and relapsing multiple myeloma. 149
Randomized trial of Fludarabine versus fludarabine and Idarubicin as Frontline treatment in patients with indolent or mantle-cell lymphoma 143
APO866 activity in hematologic malignancies: a preclinical in vitro study. 143
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 143
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study 142
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 139
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 134
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 134
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia 132
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 132
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. 131
Anaplastic large cell lymphoma: a clinicopathologic study of 53 patients. 128
HIV-related malignant lymphoma: a report of 46 cases observed in Italy. 128
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 127
Thalidomide in agnogenic and secondary myelofibrosis 127
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 127
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 127
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 127
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma 126
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. 124
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF 124
Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. 123
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 123
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 122
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 121
Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report 120
New insights into biology of chronic myeloid leukemia: implications in therapy. 120
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. 119
Targeting of a plasma cell line with a conjugate containing xanthine oxidase and the monoclonal antibody 62B1. 119
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 119
Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells 117
Hodgkin's disease (HD): a historical perspective. 117
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 117
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 117
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 116
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 116
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. 116
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 116
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 116
An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells. 115
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 115
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 115
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 114
Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. 113
Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. 113
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. 113
Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis 112
IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia 112
CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report. 112
Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. 111
Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre study. 111
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. 111
Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma 110
Prognostic variables and clinical staging in multiple myeloma. 110
Bone marrow transplantation in multiple myeloma. 110
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 110
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. 110
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 110
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 110
Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. 109
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura 109
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 109
Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. 108
High-dose melphalan for multiple myeloma. 108
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 108
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 108
The value of lymph node biopsy in patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex (ARC): a morphological and immunohistochemical study of 90 cases. 107
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 107
CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence. 107
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 107
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor V? 2 T lymphocytes in non-Hodgkin lymphomas 106
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 106
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 106
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 105
Secondary cutaneous plasmacytoma. 105
An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. 105
Laparoscopic splenectomy for hematological diseases. 104
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. 104
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. 103
[Allogeneic bone marrow transplantation in multiple myeloma]. 103
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 103
Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. 103
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 103
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. 103
Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis. 102
FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. 102
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 102
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 102
A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies. 101
Cytoskeleton organization of normal and neoplastic lymphocytes and lymphoid cell lines of T and B origin. 101
Evidence for killing of Mesenchymal Stem Cells (MSC) by autologous natural killer lymphocytes. 101
Long survival in acute myelogenous leukaemia: an international collaborative study. 101
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. 100
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 100
Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. 100
Totale 11.707
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.066
article - articoli 52.550
book - libri 0
conference - conferenze 138
curatela - curatele 0
other - altro 198
patent - brevetti 0
selected - selezionate 0
volume - volumi 180
Totale 106.132
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.355 0 0 0 0 0 0 0 0 0 260 600 495
2019/20206.745 251 157 319 521 667 747 1.069 402 562 1.106 682 262
2020/20211.517 96 158 84 103 100 147 74 137 151 175 138 154
2021/20222.859 78 210 206 294 175 180 159 682 94 296 99 386
2022/20232.853 307 165 38 274 509 555 11 236 473 35 212 38
2023/20241.145 70 189 33 144 128 300 61 134 64 22 0 0
Totale 22.923